The approach based on biomarker-defined clusters would identify responders to biologics [27], for example, in a study of the anti-IL-5 biological agent reslizumab, it was found that in the patients with bilateral nasal polyps, only elevated IL-5 levels (>40 pg/mL) in nasal secretions before treatment benefited from anti-IL-5 treatment [56]. Here, IL5 is linked to nasal cavity polyp.